Viewing StudyNCT00518206

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-05 @ 6:37 PM
Last Modification Date: 2024-10-26 @ 9:35 AM
Study NCT ID: NCT00518206
Status: COMPLETED
Last Update Posted: 2022-10-25
First Post: 2007-08-16
Brief Title: Study of NY-ESO-1 ISCOMATRIX in Patients With Measurable Stage III or IV Melanoma
Sponsor: Ludwig Institute for Cancer Research
Organization: Ludwig Institute for Cancer Research
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Melanoma
Keywords:
Name View
Clinical Trial View
Phase 2 View
Cancer Vaccine View
NY-ESO-1 protein human View
ISCOMATRIX immunological adjuvant View
Cyclophosphamide View
T-Cells Regulatory View